25 XP   0   0   10

Innate Pharma
Buy, Hold or Sell?

Let's analyse Innate Pharma together

PenkeI guess you are interested in Innate Pharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Innate Pharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Innate Pharma

I send you an email if I find something interesting about Innate Pharma.

Quick analysis of Innate Pharma (30 sec.)










What can you expect buying and holding a share of Innate Pharma? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.68
Expected worth in 1 year
$0.64
How sure are you?
31.8%

+ What do you gain per year?

Total Gains per Share
$-0.04
Return On Investment
-1.6%

For what price can you sell your share?

Current Price per Share
$2.44
Expected price per share
$2.268 - $3.068
How sure are you?
50%

1. Valuation of Innate Pharma (5 min.)




Live pricePrice per Share (EOD)

$2.44

Intrinsic Value Per Share

$-19.15 - $-22.84

Total Value Per Share

$-18.46 - $-22.16

2. Growth of Innate Pharma (5 min.)




Is Innate Pharma growing?

Current yearPrevious yearGrowGrow %
How rich?$55.2m$75.1m-$17.8m-31.1%

How much money is Innate Pharma making?

Current yearPrevious yearGrowGrow %
Making money-$5.9m-$23.7m$17.8m297.8%
Net Profit Margin-35.8%-322.0%--

How much money comes from the company's main activities?

3. Financial Health of Innate Pharma (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#467 / 1016

Most Revenue
#150 / 1016

Most Profit
#516 / 1016

Most Efficient
#489 / 1016

What can you expect buying and holding a share of Innate Pharma? (5 min.)

Welcome investor! Innate Pharma's management wants to use your money to grow the business. In return you get a share of Innate Pharma.

What can you expect buying and holding a share of Innate Pharma?

First you should know what it really means to hold a share of Innate Pharma. And how you can make/lose money.

Speculation

The Price per Share of Innate Pharma is $2.44. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Innate Pharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Innate Pharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.68. Based on the TTM, the Book Value Change Per Share is $-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Innate Pharma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.12-5.0%-0.08-3.2%-0.20-8.0%-0.12-4.9%-0.09-3.8%
Usd Book Value Change Per Share0.000.0%-0.01-0.4%-0.18-7.2%-0.25-10.2%0.031.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%-0.01-0.4%-0.18-7.2%-0.25-10.2%0.031.3%
Usd Price Per Share2.88-2.92-2.82-3.66-3.16-
Price to Earnings Ratio-5.89-19.61-19.00-7.61-6.57-
Price-to-Total Gains Ratio42.38-16.20-7.52-7.52-
Price to Book Ratio4.21-4.16-3.41-2.62-2.26-
Price-to-Total Gains Ratio42.38-16.20-7.52-7.52-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.44
Number of shares409
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.01-0.25
Usd Total Gains Per Share-0.01-0.25
Gains per Quarter (409 shares)-4.04-101.88
Gains per Year (409 shares)-16.16-407.53
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-16-260-408-418
20-32-420-815-826
30-48-580-1223-1234
40-65-740-1630-1642
50-81-900-2038-2050
60-97-1060-2445-2458
70-113-1220-2853-2866
80-129-1380-3260-3274
90-145-1540-3668-3682
100-162-1700-4075-4090

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.02.00.033.3%6.05.00.054.5%7.012.00.036.8%10.012.00.045.5%10.012.00.045.5%
Book Value Change Per Share1.01.01.033.3%3.05.03.027.3%5.08.06.026.3%7.09.06.031.8%7.09.06.031.8%
Dividend per Share0.00.03.00.0%0.00.011.00.0%0.00.019.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share1.01.01.033.3%3.05.03.027.3%5.08.06.026.3%7.09.06.031.8%7.09.06.031.8%

Fundamentals of Innate Pharma

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Fundamental data was last updated by Penke on 2024-04-11 12:07:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Innate Pharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Innate Pharma earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Innate Pharma to the Biotechnology industry mean.
  • A Net Profit Margin of -56.1% means that $-0.56 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Innate Pharma:

  • The MRQ is -56.1%. The company is making a huge loss. -2
  • The TTM is -35.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-56.1%TTM-35.8%-20.3%
TTM-35.8%YOY-322.0%+286.2%
TTM-35.8%5Y-88.7%+52.9%
5Y-88.7%10Y-73.1%-15.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-56.1%-199.6%+143.5%
TTM-35.8%-213.0%+177.2%
YOY-322.0%-279.3%-42.7%
5Y-88.7%-438.4%+349.7%
10Y-73.1%-605.5%+532.4%
1.1.2. Return on Assets

Shows how efficient Innate Pharma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Innate Pharma to the Biotechnology industry mean.
  • -5.0% Return on Assets means that Innate Pharma generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Innate Pharma:

  • The MRQ is -5.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.0%TTM-3.1%-2.0%
TTM-3.1%YOY-10.9%+7.9%
TTM-3.1%5Y-4.9%+1.8%
5Y-4.9%10Y-3.9%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.0%-13.5%+8.5%
TTM-3.1%-12.9%+9.8%
YOY-10.9%-11.8%+0.9%
5Y-4.9%-14.1%+9.2%
10Y-3.9%-16.0%+12.1%
1.1.3. Return on Equity

Shows how efficient Innate Pharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Innate Pharma to the Biotechnology industry mean.
  • -17.9% Return on Equity means Innate Pharma generated $-0.18 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Innate Pharma:

  • The MRQ is -17.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -10.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.9%TTM-10.9%-7.0%
TTM-10.9%YOY-42.9%+31.9%
TTM-10.9%5Y-14.5%+3.6%
5Y-14.5%10Y-11.8%-2.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.9%-16.9%-1.0%
TTM-10.9%-16.1%+5.2%
YOY-42.9%-15.1%-27.8%
5Y-14.5%-19.9%+5.4%
10Y-11.8%-20.9%+9.1%

1.2. Operating Efficiency of Innate Pharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Innate Pharma is operating .

  • Measures how much profit Innate Pharma makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Innate Pharma to the Biotechnology industry mean.
  • An Operating Margin of -103.6% means the company generated $-1.04  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Innate Pharma:

  • The MRQ is -103.6%. The company is operating very inefficient. -2
  • The TTM is -74.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-103.6%TTM-74.0%-29.6%
TTM-74.0%YOY-135.9%+61.9%
TTM-74.0%5Y-56.6%-17.5%
5Y-56.6%10Y-45.4%-11.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-103.6%-295.1%+191.5%
TTM-74.0%-225.8%+151.8%
YOY-135.9%-288.4%+152.5%
5Y-56.6%-477.4%+420.8%
10Y-45.4%-625.6%+580.2%
1.2.2. Operating Ratio

Measures how efficient Innate Pharma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.95 means that the operating costs are $1.95 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Innate Pharma:

  • The MRQ is 1.949. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.796. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.949TTM1.796+0.153
TTM1.796YOY3.565-1.769
TTM1.7965Y1.617+0.179
5Y1.61710Y1.573+0.044
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9493.090-1.141
TTM1.7963.264-1.468
YOY3.5653.783-0.218
5Y1.6175.679-4.062
10Y1.5737.894-6.321

1.3. Liquidity of Innate Pharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Innate Pharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.73 means the company has $3.73 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Innate Pharma:

  • The MRQ is 3.734. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.768. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.734TTM3.768-0.034
TTM3.768YOY3.234+0.534
TTM3.7685Y2.834+0.934
5Y2.83410Y2.699+0.135
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7343.914-0.180
TTM3.7684.220-0.452
YOY3.2345.388-2.154
5Y2.8346.045-3.211
10Y2.6996.406-3.707
1.3.2. Quick Ratio

Measures if Innate Pharma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Innate Pharma to the Biotechnology industry mean.
  • A Quick Ratio of 4.06 means the company can pay off $4.06 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Innate Pharma:

  • The MRQ is 4.057. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.214. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.057TTM4.214-0.157
TTM4.214YOY3.043+1.171
TTM4.2145Y2.629+1.585
5Y2.62910Y2.412+0.216
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0573.572+0.485
TTM4.2143.998+0.216
YOY3.0435.390-2.347
5Y2.6295.969-3.340
10Y2.4126.287-3.875

1.4. Solvency of Innate Pharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Innate Pharma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Innate Pharma to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.72 means that Innate Pharma assets are financed with 71.8% credit (debt) and the remaining percentage (100% - 71.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Innate Pharma:

  • The MRQ is 0.718. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.715. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.718TTM0.715+0.003
TTM0.715YOY0.693+0.022
TTM0.7155Y0.564+0.152
5Y0.56410Y0.566-0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7180.336+0.382
TTM0.7150.334+0.381
YOY0.6930.269+0.424
5Y0.5640.366+0.198
10Y0.5660.390+0.176
1.4.2. Debt to Equity Ratio

Measures if Innate Pharma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Innate Pharma to the Biotechnology industry mean.
  • A Debt to Equity ratio of 254.9% means that company has $2.55 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Innate Pharma:

  • The MRQ is 2.549. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.513. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.549TTM2.513+0.036
TTM2.513YOY2.382+0.131
TTM2.5135Y1.509+1.004
5Y1.50910Y1.500+0.008
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5490.382+2.167
TTM2.5130.396+2.117
YOY2.3820.335+2.047
5Y1.5090.434+1.075
10Y1.5000.465+1.035

2. Market Valuation of Innate Pharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Innate Pharma generates.

  • Above 15 is considered overpriced but always compare Innate Pharma to the Biotechnology industry mean.
  • A PE ratio of -5.89 means the investor is paying $-5.89 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Innate Pharma:

  • The EOD is -4.987. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.887. Based on the earnings, the company is expensive. -2
  • The TTM is 19.607. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-4.987MRQ-5.887+0.899
MRQ-5.887TTM19.607-25.493
TTM19.607YOY19.000+0.607
TTM19.6075Y7.605+12.001
5Y7.60510Y6.568+1.037
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.987-2.259-2.728
MRQ-5.887-2.569-3.318
TTM19.607-2.664+22.271
YOY19.000-4.120+23.120
5Y7.605-6.258+13.863
10Y6.568-6.171+12.739
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Innate Pharma:

  • The EOD is -2.002. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.363. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.266. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.002MRQ-2.363+0.361
MRQ-2.363TTM-3.266+0.903
TTM-3.266YOY15.974-19.240
TTM-3.2665Y14.028-17.294
5Y14.02810Y12.115+1.913
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.002-2.924+0.922
MRQ-2.363-3.246+0.883
TTM-3.266-3.488+0.222
YOY15.974-5.620+21.594
5Y14.028-8.315+22.343
10Y12.115-8.826+20.941
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Innate Pharma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.21 means the investor is paying $4.21 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Innate Pharma:

  • The EOD is 3.570. Based on the equity, the company is fair priced.
  • The MRQ is 4.214. Based on the equity, the company is fair priced.
  • The TTM is 4.164. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.570MRQ4.214-0.644
MRQ4.214TTM4.164+0.050
TTM4.164YOY3.415+0.749
TTM4.1645Y2.620+1.544
5Y2.62010Y2.263+0.357
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.5701.851+1.719
MRQ4.2142.090+2.124
TTM4.1642.095+2.069
YOY3.4152.844+0.571
5Y2.6203.466-0.846
10Y2.2633.815-1.552
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Innate Pharma.

3.1. Institutions holding Innate Pharma

Institutions are holding 0.102% of the shares of Innate Pharma.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Exchange Traded Concepts, LLC0.0580.0035468881189033.9734
2023-12-31Morgan Stanley - Brokerage Accounts0.057304635414003.1143
2023-12-31Optiver Holding B.V.0.0281022705-167514-88.0638
2023-12-31Millennium Management LLC0.0148012002-34971-74.4492
2023-12-31Barclays PLC0.0005041200
2023-12-31Rhumbline Advisers0.0003020500
2023-12-31Steward Partners Investment Advisory, LLC0.00020200-300-60
2023-12-31UBS Group AG0.0002014600
2023-12-31Oxford Asset Management, LLC000-29397-100
2023-09-30Citadel Advisors Llc000-13281-100
Total 0.15940.0035128912-232173-180.1%

3.2. Funds holding Innate Pharma

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28Loncar Cancer Immunotherapy ETF0.10710.8674865781500620.9663
2024-03-28ActivePassive International Equity ETF0.030.0248242661800.7473
2023-10-20Loncar China BioPharma ETF0.0211.06481700200
2024-03-29Dimensional International Sstby Cr 1 ETF004000
Total 0.15811.957127886+15186+11.9%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Innate Pharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share----0.0100%-0.1750%-0.2490%0.031-100%
Book Value Per Share--0.6830.701-2%0.919-26%1.502-55%1.668-59%
Current Ratio--3.7343.768-1%3.234+15%2.834+32%2.699+38%
Debt To Asset Ratio--0.7180.715+0%0.693+4%0.564+27%0.566+27%
Debt To Equity Ratio--2.5492.513+1%2.382+7%1.509+69%1.500+70%
Dividend Per Share----0%-0%-0%-0%
Eps---0.122-0.078-36%-0.195+60%-0.119-3%-0.093-24%
Free Cash Flow Per Share---0.305-0.253-17%-0.119-61%-0.107-65%-0.083-73%
Free Cash Flow To Equity Per Share---0.314-0.265-16%-0.129-59%-0.001-100%0.033-1042%
Gross Profit Margin--1.0000.986+1%0.973+3%0.973+3%0.977+2%
Intrinsic Value_10Y_max---22.840--------
Intrinsic Value_10Y_min---19.145--------
Intrinsic Value_1Y_max---0.776--------
Intrinsic Value_1Y_min---0.761--------
Intrinsic Value_3Y_max---3.485--------
Intrinsic Value_3Y_min---3.304--------
Intrinsic Value_5Y_max---7.583--------
Intrinsic Value_5Y_min---6.939--------
Market Cap197254480.000-18%232824960.000238936722.733-3%231407794.405+1%298273864.112-22%257600155.370-10%
Net Profit Margin---0.561-0.358-36%-3.220+474%-0.887+58%-0.731+30%
Operating Margin---1.036-0.740-29%-1.359+31%-0.566-45%-0.454-56%
Operating Ratio--1.9491.796+9%3.565-45%1.617+20%1.573+24%
Pb Ratio3.570-18%4.2144.164+1%3.415+23%2.620+61%2.263+86%
Pe Ratio-4.987+15%-5.88719.607-130%19.000-131%7.605-177%6.568-190%
Price Per Share2.440-18%2.8802.918-1%2.820+2%3.664-21%3.165-9%
Price To Free Cash Flow Ratio-2.002+15%-2.363-3.266+38%15.974-115%14.028-117%12.115-120%
Quick Ratio--4.0574.214-4%3.043+33%2.629+54%2.412+68%
Return On Assets---0.050-0.031-39%-0.109+117%-0.049-3%-0.039-22%
Return On Equity---0.179-0.109-39%-0.429+140%-0.145-19%-0.118-34%
Total Gains Per Share----0.0100%-0.1750%-0.2490%0.031-100%
Usd Book Value--55253804.60057369519.667-4%75186842.700-27%161410686.528-66%191525328.805-71%
Usd Book Value Change Per Share----0.0100%-0.1750%-0.2490%0.031-100%
Usd Book Value Per Share--0.6830.701-2%0.919-26%1.502-55%1.668-59%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.122-0.078-36%-0.195+60%-0.119-3%-0.093-24%
Usd Free Cash Flow---24629519.935-20598944.690-16%-9689856.125-61%-8213666.686-67%-5652587.705-77%
Usd Free Cash Flow Per Share---0.305-0.253-17%-0.119-61%-0.107-65%-0.083-73%
Usd Free Cash Flow To Equity Per Share---0.314-0.265-16%-0.129-59%-0.001-100%0.033-1042%
Usd Market Cap197254480.000-18%232824960.000238936722.733-3%231407794.405+1%298273864.112-22%257600155.370-10%
Usd Price Per Share2.440-18%2.8802.918-1%2.820+2%3.664-21%3.165-9%
Usd Profit---9888004.800-5982342.267-39%-23798600.700+141%-15545005.347+57%-11086396.728+12%
Usd Revenue--17626581.13524293461.557-27%20153143.884-13%22256728.117-21%28797224.321-39%
Usd Total Gains Per Share----0.0100%-0.1750%-0.2490%0.031-100%
 EOD+2 -5MRQTTM+3 -26YOY+16 -135Y+8 -2110Y+8 -25

4.2. Fundamental Score

Let's check the fundamental score of Innate Pharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.987
Price to Book Ratio (EOD)Between0-13.570
Net Profit Margin (MRQ)Greater than0-0.561
Operating Margin (MRQ)Greater than0-1.036
Quick Ratio (MRQ)Greater than14.057
Current Ratio (MRQ)Greater than13.734
Debt to Asset Ratio (MRQ)Less than10.718
Debt to Equity Ratio (MRQ)Less than12.549
Return on Equity (MRQ)Greater than0.15-0.179
Return on Assets (MRQ)Greater than0.05-0.050
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Innate Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.300
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets184,193
Total Liabilities132,292
Total Stockholder Equity51,901
 As reported
Total Liabilities 132,292
Total Stockholder Equity+ 51,901
Total Assets = 184,193

Assets

Total Assets184,193
Total Current Assets148,012
Long-term Assets36,181
Total Current Assets
Cash And Cash Equivalents 70,605
Short-term Investments 21,851
Net Receivables 46,489
Other Current Assets 9,067
Total Current Assets  (as reported)148,012
Total Current Assets  (calculated)148,012
+/-0
Long-term Assets
Property Plant Equipment 6,322
Long-term Assets Other 10,641
Long-term Assets  (as reported)36,181
Long-term Assets  (calculated)16,963
+/- 19,218

Liabilities & Shareholders' Equity

Total Current Liabilities39,637
Long-term Liabilities92,655
Total Stockholder Equity51,901
Total Current Liabilities
Short-term Debt 8,936
Accounts payable 8,561
Other Current Liabilities 16,275
Total Current Liabilities  (as reported)39,637
Total Current Liabilities  (calculated)33,772
+/- 5,865
Long-term Liabilities
Long-term Liabilities  (as reported)92,655
Long-term Liabilities  (calculated)0
+/- 92,655
Total Stockholder Equity
Common Stock4,044
Retained Earnings -336,893
Accumulated Other Comprehensive Income 495
Other Stockholders Equity 384,255
Total Stockholder Equity (as reported)51,901
Total Stockholder Equity (calculated)51,901
+/-0
Other
Cash and Short Term Investments 92,456
Common Stock Shares Outstanding 80,842
Current Deferred Revenue5,865
Liabilities and Stockholders Equity 184,193
Net Debt -30,712
Net Working Capital 108,375
Short Long Term Debt Total 39,893



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2024-03-312023-12-312023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302017-12-312017-06-302016-12-312016-06-302015-12-312015-06-302014-12-312014-06-302013-12-312013-06-302012-12-312012-06-302011-12-312011-06-302010-12-312010-06-302009-12-31
> Total Assets 
64,219
55,292
48,010
41,479
60,109
55,817
48,295
41,820
55,882
103,468
90,690
305,083
305,956
282,356
281,577
246,384
255,023
225,916
522,362
451,216
1,393,212
352,555
1,127,878
401,361
401,361
333,066
0
307,423
307,423
266,217
0
267,496
267,496
280,430
207,863
199,049
207,863
199,049
184,193
184,193
184,193184,193199,049207,863199,049207,863280,430267,496267,4960266,217307,423307,4230333,066401,361401,3611,127,878352,5551,393,212451,216522,362225,916255,023246,384281,577282,356305,956305,08390,690103,46855,88241,82048,29555,81760,10941,47948,01055,29264,219
   > Total Current Assets 
56,266
47,614
40,664
33,709
52,975
48,255
40,997
35,144
49,350
90,958
79,314
294,450
252,126
224,871
230,078
195,772
137,521
122,642
370,043
319,643
856,259
216,678
237,605
237,605
237,605
163,689
173,451
173,332
173,332
129,688
138,256
138,256
138,256
171,797
139,831
144,455
139,831
144,455
148,012
148,012
148,012148,012144,455139,831144,455139,831171,797138,256138,256138,256129,688173,332173,332173,451163,689237,605237,605237,605216,678856,259319,643370,043122,642137,521195,772230,078224,871252,126294,45079,31490,95849,35035,14440,99748,25552,97533,70940,66447,61456,266
       Cash And Cash Equivalents 
46,448
36,391
31,818
29,654
46,606
37,739
30,584
22,751
38,360
73,969
64,286
274,767
152,870
159,852
175,906
151,003
99,367
79,502
176,330
152,314
590,298
149,376
570,140
202,887
202,887
131,542
0
136,792
136,792
103,980
0
103,756
103,756
102,949
84,225
71,414
84,225
71,414
70,605
70,605
70,60570,60571,41484,22571,41484,225102,949103,756103,7560103,980136,792136,7920131,542202,887202,887570,140149,376590,298152,314176,33079,50299,367151,003175,906159,852152,870274,76764,28673,96938,36022,75130,58437,73946,60629,65431,81836,39146,448
       Short-term Investments 
2,746
2,751
2,763
0
0
0
2,032
1,988
2,989
4,944
4,952
4,158
83,040
44,075
21,782
20,481
16,743
17,379
17,616
15,217
61,560
15,578
44,900
15,978
15,978
16,199
0
14,845
14,845
15,341
0
16,080
16,080
20,401
17,260
17,475
17,260
17,475
21,851
21,851
21,85121,85117,47517,26017,47517,26020,40116,08016,080015,34114,84514,845016,19915,97815,97844,90015,57861,56015,21717,61617,37916,74320,48121,78244,07583,0404,1584,9524,9442,9891,9882,0320002,7632,7512,746
       Net Receivables 
7,071
0
6,083
0
0
0
7,229
9,284
7,062
10,054
8,585
11,885
9,948
13,122
25,554
17,536
15,084
21,614
169,758
146,637
174,857
44,248
18,740
13,141
13,141
15,948
21,814
21,695
21,695
10,368
13,474
18,420
18,420
41,830
3,080
2,934
38,346
55,566
55,557
46,489
46,48955,55755,56638,3462,9343,08041,83018,42018,42013,47410,36821,69521,69521,81415,94813,14113,14118,74044,248174,857146,637169,75821,61415,08417,53625,55413,1229,94811,8858,58510,0547,0629,2847,2290006,08307,071
       Other Current Assets 
1
100
0
4,055
6,369
10,516
1
1,121
-1
1,991
1
3,640
6,268
7,822
6,836
6,752
-1
4,147
1,463
5,475
2,794
7,476
0
-1
-1
9,886
0
7,947
7,947
-1
2,364
21,814
21,814
6,617
35,266
52,632
2
6,474
-1
9,067
9,067-16,474252,63235,2666,61721,81421,8142,364-17,9477,94709,886-1-107,4762,7945,4751,4634,147-16,7526,8367,8226,2683,64011,991-11,121110,5166,3694,05501001
   > Long-term Assets 
7,953
7,678
7,346
7,770
7,134
7,562
7,299
6,678
6,532
12,509
11,377
10,632
53,830
57,485
51,499
50,612
117,501
103,274
0
131,574
0
135,877
0
163,756
163,756
169,377
0
134,091
134,091
136,528
0
129,241
129,241
108,633
45,217
43,955
68,033
54,594
36,181
36,181
36,18136,18154,59468,03343,95545,217108,633129,241129,2410136,528134,091134,0910169,377163,756163,7560135,8770131,5740103,274117,50150,61251,49957,48553,83010,63211,37712,5096,5326,6787,2997,5627,1347,7707,3467,6787,953
       Property Plant Equipment 
7,943
7,667
7,335
6,770
6,442
6,890
6,824
6,535
6,258
6,054
5,931
5,816
6,304
7,820
9,094
9,834
10,729
10,674
11,827
10,216
11,398
11,398
11,672
11,672
11,672
12,434
11,694
11,694
11,694
10,891
10,174
10,174
10,174
9,556
8,542
7,262
8,542
7,262
6,322
6,322
6,3226,3227,2628,5427,2628,5429,55610,17410,17410,17410,89111,69411,69411,69412,43411,67211,67211,67211,39811,39810,21611,82710,67410,7299,8349,0947,8206,3045,8165,9316,0546,2586,5356,8246,8906,4426,7707,3357,6677,943
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
2
2
0
0
-40,997
-40,997
0
0
0
000-40,997-40,99700220011000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
38,363
38,011
139,576
35,320
103,989
37,005
0
36,872
0
38,934
0
40,081
0
39,878
0
34,806
0
35,119
0
35,790
9,796
0
09,79635,790035,119034,806039,878040,081038,934036,872037,005103,98935,320139,57638,01138,363000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
6,347
5,362
4,732
9,732
9,995
9,075
7,720
46,192
44,901
97,857
84,529
347,284
87,881
272,493
96,967
96,967
112,549
0
46,288
46,288
0
0
44,190
44,190
43,250
1,556
903
42,553
903
416
0
041690342,5539031,55643,25044,19044,1900046,28846,2880112,54996,96796,967272,49387,881347,28484,52997,85744,90146,1927,7209,0759,9959,7324,7325,3626,347000000000
       Long-term Assets Other 
10
11
11
1,000
692
672
0
-2
2
6
84
84
37,794
0
355
427
111
86
0
87
0
87
0
16,826
16,826
23,587
0
30,087
30,087
34,963
0
29,969
29,969
13,243
-45,217
-43,955
14,248
965
87
10,641
10,6418796514,248-43,955-45,21713,24329,96929,969034,96330,08730,087023,58716,82616,826087087086111427355037,794848462-206726921,000111110
> Total Liabilities 
17,097
14,786
14,494
13,292
33,484
31,169
24,931
20,339
15,596
18,447
16,064
235,905
233,889
213,152
195,408
177,475
169,067
138,745
328,752
283,976
676,893
171,289
516,910
183,945
183,945
125,302
0
151,448
151,448
132,656
0
160,056
160,056
164,097
153,712
141,186
153,712
141,186
132,292
132,292
132,292132,292141,186153,712141,186153,712164,097160,056160,0560132,656151,448151,4480125,302183,945183,945516,910171,289676,893283,976328,752138,745169,067177,475195,408213,152233,889235,90516,06418,44715,59620,33924,93131,16933,48413,29214,49414,78617,097
   > Total Current Liabilities 
9,265
7,283
7,374
7,883
15,494
17,707
15,364
14,952
9,278
12,735
10,775
57,834
60,163
79,239
76,441
76,027
73,909
67,216
227,758
196,737
373,635
94,549
121,822
121,822
121,822
82,345
45,488
46,694
46,694
42,619
79,886
79,886
79,886
73,561
41,338
37,667
41,338
37,667
39,637
39,637
39,63739,63737,66741,33837,66741,33873,56179,88679,88679,88642,61946,69446,69445,48882,345121,822121,822121,82294,549373,635196,737227,75867,21673,90976,02776,44179,23960,16357,83410,77512,7359,27814,95215,36417,70715,4947,8837,3747,2839,265
       Short-term Debt 
723
0
701
0
13,221
0
1,178
1,161
613
444
453
462
622
852
1,264
1,202
1,343
1,355
0
1,347
0
1,722
0
2,130
2,130
2,035
0
2,142
2,142
2,017
0
30,748
30,748
30,851
0
2,102
2,102
5,335
8,936
8,936
8,9368,9365,3352,1022,102030,85130,74830,74802,0172,1422,14202,0352,1302,13001,72201,34701,3551,3431,2021,2648526224624534446131,1611,178013,22107010723
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
456
452
2,007
354
5,986
1,493
0
2,035
0
2,142
0
2,017
0
30,748
0
30,851
0
1,263
0
0
8,451
0
08,451001,263030,851030,74802,01702,14202,03501,4935,9863542,007452456000000000000000000
       Accounts payable 
8,369
6,518
6,660
5,797
0
16,423
4,670
4,773
5,141
9,639
6,846
7,004
59,541
10,777
15,599
14,707
19,970
21,828
48,247
41,676
91,420
23,134
27,936
27,936
27,936
26,544
20,731
29,539
29,539
17,026
14,730
28,573
28,573
12,924
13,656
9,868
20,911
18,991
17,018
8,561
8,56117,01818,99120,9119,86813,65612,92428,57328,57314,73017,02629,53929,53920,73126,54427,93627,93627,93623,13491,42041,67648,24721,82819,97014,70715,59910,77759,5417,0046,8469,6395,1414,7734,67016,42305,7976,6606,5188,369
       Other Current Liabilities 
173
765
13
2,086
2,273
1,284
1,853
1,355
2,265
1,767
2,591
2,987
0
2,845
4,666
3,475
4,687
22,716
177,951
71,618
274,801
27,426
91,756
42,986
42,986
12,185
22,615
2,508
2,508
13,112
34,408
8,065
8,065
20,692
27,682
27,799
11,765
8,291
7,818
16,275
16,2757,8188,29111,76527,79927,68220,6928,0658,06534,40813,1122,5082,50822,61512,18542,98642,98691,75627,426274,80171,618177,95122,7164,6873,4754,6662,84502,9872,5911,7672,2651,3551,8531,2842,2732,08613765173
   > Long-term Liabilities 
7,832
7,503
7,120
5,409
17,990
13,462
9,567
5,387
6,318
5,712
5,289
178,071
173,726
133,913
118,967
101,448
95,158
71,529
0
87,239
0
76,740
0
62,123
62,123
42,957
0
104,754
104,754
90,037
0
80,170
80,170
90,536
38,929
34,804
112,374
103,519
92,655
92,655
92,65592,655103,519112,37434,80438,92990,53680,17080,170090,037104,754104,754042,95762,12362,123076,740087,239071,52995,158101,448118,967133,913173,726178,0715,2895,7126,3185,3879,56713,46217,9905,4097,1207,5037,832
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
97,319
96,426
73,503
73,503
45,530
45,530
26,176
26,176
89,014
87,809
75,552
75,552
66,667
66,667
78,013
78,013
72,225
72,225
68,196
68,196
0
0
0068,19668,19672,22572,22578,01378,01366,66766,66775,55275,55287,80989,01426,17626,17645,53045,53073,50373,50396,42697,319000000000000000000
> Total Stockholder Equity
47,122
40,506
33,516
28,187
26,625
24,648
23,364
21,481
40,286
85,021
74,626
69,178
72,067
69,204
86,169
68,909
85,956
87,171
193,610
167,240
716,319
181,266
610,968
217,416
217,416
207,764
0
155,975
155,975
133,561
0
107,440
107,440
116,333
54,151
57,863
54,151
57,863
51,901
51,901
51,90151,90157,86354,15157,86354,151116,333107,440107,4400133,561155,975155,9750207,764217,416217,416610,968181,266716,319167,240193,61087,17185,95668,90986,16969,20472,06769,17874,62685,02140,28621,48123,36424,64826,62528,18733,51640,50647,122
   Common Stock
1,832
1,884
1,884
1,884
1,884
1,884
1,897
1,907
2,287
2,648
2,648
2,676
2,692
2,695
2,696
2,701
2,880
2,880
3,701
3,197
3,203
3,203
3,941
3,941
3,941
3,946
3,950
3,950
3,950
3,952
3,978
3,978
3,978
3,988
4,011
4,027
4,011
4,027
4,044
4,044
4,0444,0444,0274,0114,0274,0113,9883,9783,9783,9783,9523,9503,9503,9503,9463,9413,9413,9413,2033,2033,1973,7012,8802,8802,7012,6962,6952,6922,6762,6482,6482,2871,9071,8971,8841,8841,8841,8841,8841,832
   Retained Earnings 
-63,223
-62,880
-76,883
-81,880
-6,980
-85,882
-87,069
-89,392
-89,964
-99,003
-109,528
-116,501
-116,231
-119,405
-103,595
-126,953
-151,980
-150,194
3,530
-134,791
-121,671
-121,671
-155,671
-155,671
-155,671
-166,053
-220,460
-220,460
-220,460
-244,150
-272,213
-272,213
-272,213
-265,938
-330,316
-328,597
-330,316
-328,597
-336,893
-336,893
-336,893-336,893-328,597-330,316-328,597-330,316-265,938-272,213-272,213-272,213-244,150-220,460-220,460-220,460-166,053-155,671-155,671-155,671-121,671-121,671-134,7913,530-150,194-151,980-126,953-103,595-119,405-116,231-116,501-109,528-99,003-89,964-89,392-87,069-85,882-6,980-81,880-76,883-62,880-63,223
   Accumulated Other Comprehensive Income 
219
-489
341
0
0
-1,265
-17
-31
-38
-61
-241
-303
-730
-574
-503
-33
180
-1,455
0
-1,099
0
-1,895
0
-472
-472
-568
0
355
355
715
0
456
456
284
0
819
819
1,064
0
495
49501,064819819028445645607153553550-568-472-4720-1,8950-1,0990-1,455180-33-503-574-730-303-241-61-38-31-17-1,26500341-489219
   Capital Surplus 0000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000
   Other Stockholders Equity 
108,294
101,991
108,174
108,183
31,721
109,911
108,553
108,997
128,001
181,437
181,747
183,306
186,336
186,488
187,571
193,194
234,876
235,940
-160,845
299,933
-1,895
301,629
-471
369,618
369,618
370,439
355
372,131
372,131
373,044
455
375,219
375,219
377,999
380,456
382,433
379,637
381,369
384,750
384,255
384,255384,750381,369379,637382,433380,456377,999375,219375,219455373,044372,131372,131355370,439369,618369,618-471301,629-1,895299,933-160,845235,940234,876193,194187,571186,488186,336183,306181,747181,437128,001108,997108,553109,91131,721108,183108,174101,991108,294



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue51,901
Cost of Revenue-0
Gross Profit51,90151,901
 
Operating Income (+$)
Gross Profit51,901
Operating Expense-69,217
Operating Income-22,409-17,316
 
Operating Expense (+$)
Research Development52,131
Selling General Administrative11,748
Selling And Marketing Expenses0
Operating Expense69,21763,879
 
Net Interest Income (+$)
Interest Income3,177
Interest Expense-1,835
Other Finance Cost-1,195
Net Interest Income2,537
 
Pretax Income (+$)
Operating Income-22,409
Net Interest Income2,537
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-17,299-27,519
EBIT - interestExpense = -24,244
-17,299
-5,735
Interest Expense1,835
Earnings Before Interest and Taxes (EBIT)-22,409-15,464
Earnings Before Interest and Taxes (EBITDA)-17,316
 
After tax Income (+$)
Income Before Tax-17,299
Tax Provision-0
Net Income From Continuing Ops-7,570-17,299
Net Income-7,570
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses74,310
Total Other Income/Expenses Net5,110-2,537
 

Technical Analysis of Innate Pharma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Innate Pharma. The general trend of Innate Pharma is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Innate Pharma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Innate Pharma.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.8871 < 2.9 < 3.068.

The bearish price targets are: 2.34 > 2.32 > 2.268.

Tweet this
Innate Pharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Innate Pharma. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Innate Pharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Innate Pharma.

Innate Pharma Daily Moving Average Convergence/Divergence (MACD) ChartInnate Pharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Innate Pharma. The current adx is .

Innate Pharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Innate Pharma.

Innate Pharma Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Innate Pharma.

Innate Pharma Daily Relative Strength Index (RSI) ChartInnate Pharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Innate Pharma.

Innate Pharma Daily Stochastic Oscillator ChartInnate Pharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Innate Pharma.

Innate Pharma Daily Commodity Channel Index (CCI) ChartInnate Pharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Innate Pharma.

Innate Pharma Daily Chande Momentum Oscillator (CMO) ChartInnate Pharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Innate Pharma.

Innate Pharma Daily Williams %R ChartInnate Pharma Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Innate Pharma.

Innate Pharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Innate Pharma.

Innate Pharma Daily Average True Range (ATR) ChartInnate Pharma Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Innate Pharma.

Innate Pharma Daily On-Balance Volume (OBV) ChartInnate Pharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Innate Pharma.

Innate Pharma Daily Money Flow Index (MFI) ChartInnate Pharma Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Innate Pharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-01ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Innate Pharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Innate Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.300
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Innate Pharma with someone you think should read this too:
  • Are you bullish or bearish on Innate Pharma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Innate Pharma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Innate Pharma

I send you an email if I find something interesting about Innate Pharma.


Comments

How you think about this?

Leave a comment

Stay informed about Innate Pharma.

Receive notifications about Innate Pharma in your mailbox!